“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of its insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between Feb 10 and 21, 2020,” said the company spokesperson in a statement.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/340IySv
via IFTTT
0 comments:
Post a Comment